Videos

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains how real-time data generated through direct-to-patient models are shaping pharma's commercial decisions.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models.

Gerren McHam of the API Innovation Center on what a resilient US pharmaceutical supply chain looks like in five to ten years, and what execution actually requires.

Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply chain independence from China actually requires.

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions.

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

Hear from Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.

Learn how to navigate growing complexity, reduce workflow fragmentation, and design access and affordability programs that support patients throughout their treatment journey.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like.

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.

Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.

Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.